muestreo HORAS Dil ln OD Growth rate (1/h)F0 14-11-16 15:00 0,00 1,00 0,00 N/AF2 14-11-16 16:30 1,50 2,10 0,74 0,49F4 14-11-16 18:00 3,00 3,00 1,10 0,24F6 15-11-16 7:30 16,50 41,00 3,71 0,19F8 15-11-16 10:30 19,50 69,00 4,23 0,17I2h 15-11-16 12:30 21,50 110,00 4,70 0,23I4h 15-11-16 14:30 23,50 131,00 4,88 0,09

I6h 15-11-16 16:30 25,50 151,00 5,02 0,07

I19h 15-11-16 18:30 27,50 168,00 5,12 0,05

I21h 16-11-16 8:30 41,50 240,00 5,48 0,03

I24h 16-11-16 11:30 44,50 310,00 5,74 0,09

I27,5h 16-11-16 13:30 46,50 330,00 5,80 0,03I30,5h 16-11-16 17:30 48,50 370,00 5,91 0,06In

duc�

on -

Fed

Batc

h ph

ase

OD600

Batc

h ph

ase

0,0

50,0

100,0

150,0

200,0

250,0

300,0

350,0

400,0

0 10 20 30 40 50 60

OD6

00

Time (h)

Batch

Fed-batch

y = 0,2054x + 0,2937R² = 0,9898

y = 0,0357x + 4,0881R² = 0,9651

0,001,002,003,004,005,006,007,00

0,00 10,00 20,00 30,00 40,00 50,00

Growth rate (1/h)Ln OD - Batch phase

Recombinant antigen EBNA1for Epstein-barr virus

EBNA1 has a predominant role in the maintenance of latent EBV infections and is expressed in all EBV infections and all EBV-associated malignant tissues. It contains a Gly-Ala repeated domain flanked by two unique regions. The central, C-terminus and N-terminus regions have been described as potentially antigenic.

The IgG antibody against Epstein-Barr Nuclear antigen-1 (EBNA-1) is not seen until 2-3 months after infection and is indicative of convalescence or prior disease. In situations where the clinical status is unclear, avidity testing of anti-VCA IgG or anti-EBNA-1 IgG is often helpful. In areas where nasopharyngeal carcinoma is common, the measurement of IgA antibodies to VCA and EBNA-1 has been helpful to stablish that diagnosis.

High Quality Raw Material for IVD Manufacturing Industry

Rekom Biotech´s recombinant antigen EBNA1 (RAG0007) has a 83% success rate in evaluations for the development of a commercial diagnostic assay.

REFERENCE

RAG0007

ANTIGEN

EBNA1

APPLICATION

ELISA, CLIA

PACK SIZE

0.1 mg to 1 mg; bulk

0

0,5

1

1,5

2

2,5

3

3,5

4

1:1000 1:4000 1:10.000

OD

450/

620

Monoclonal �ter

lot 17-001

lot 16-002

Tel: +34 958 63 70 85 - E-mail: info@rekombiotech.com - Web: www.rekombiotech.com

Time

Ant

ibod

y tit

er

EBV Infection Kinetics

EA IgG

EBNA IgG

VCA IgM

Primary Infection Convalescence Chronic/Reactived

VCA IgG

EBV is an enveloped virus with a DNA core surrounded by a protein capsid. This capsid is surrounded by a protein tegument, which in turn is contained in a lipid envelope. The EBV genome is a linear, double stranded DNA molecule that encodes more than 85 genes.

Infection by EBV results in the production of antibodies to 4 distinct antigen complexes: EBV-induced nuclear antigen (EBNA), EBV-induced early antigen (EA), viral capsid antigen (VCA) and EBV-induced membrane antigen (MA).

The six EBV capsid proteins are BcLF1 (major capsid protein), BORF1 (triplex 1), BDLF1 (triplex 2), BdRF1 (scaffold protein), BVRF2 (protease), and BFRF3 (small capsid protein).

The nuclear antigen protein EBNA1 is a highly prevalent target for IgG antibody respon-ses.

EBV, also called human herpes virus 4, belongs to the herpesvirus family. EBV was first identified in 1964 by Epstein’s group in a cell line derived from Burkitt’s lymphoma. Sero-epidemiologic studies indicate that more than 90% of adults worldwide are infected with EBV. In developing countries, infection occurs early in life, and most early childhood infections are subclinical. In more affluent Western societies, when primary infection is delayed until later childhood or adolescence, it manifests in approximately 25–75% of cases as infectious mononucleosis. The primary site of EBV infection is the oropharynx and the virus is capable of infecting both B cells and epithelial cells and switching between the two. As many as 20-30% of healthy adults who are previously infected with EBV, shed the virus in low concen¬trations in oral secretions. EBV is also found in female and male genital secretions and can be transmitted by sexual contact.

Also, EBV is the first human virus to be directly implicated in carcinogenesis. In some people, the latent virus is capable of causing malignant tumours, such as nasopharyngeal carcinoma and various B- and T-cell lympho-mas, at sites including the head, neck and oropharyngeal region.

Epstein-barr virus infection